Latest Strategic Collaborations News

Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.

Osmond Resources is progressing its Orión EU Critical Minerals Project with promising drilling results, positive mineral processing testwork, and a new partnership targeting rare earth carbonate production in Spain.

PT ANTAM TBK sustained strong operational performance in Q1 2026 with robust gold and nickel sales amid favourable market trends, while pushing forward strategic mineral downstreaming projects including Indonesia's integrated battery ecosystem.

HighCom Technology secures a nearly A$10 million contract from the Australian Defence for counter small uncrewed aerial systems, marking its first major C-UAS order and reinforcing its defence sector presence.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Aurora Labs has made significant strides in commercial propulsion delivery and deepened its partnership with European defence giant MBDA, while scaling manufacturing capabilities and reinforcing its Board with defence expertise.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Brazilian Critical Minerals (ASX: BCM) has boosted the indicated mineral resource at its Ema rare earth project by 58%, now totalling 1.07 billion tonnes at 732 ppm TREO. This positions Ema as one of the world’s largest ionic clay rare earth deposits and the only ISR-ready project in the western world.

Comvita launches a NZ$30 million renounceable Rights Offer to refinance debt and bring Southeast Asian consumer giant Fraser and Neave onboard as a strategic investor with a near 20% stake.

Telix Pharmaceuticals and Regeneron have entered a strategic collaboration to co-develop next-generation radiopharmaceutical therapies, with Telix receiving a $40 million upfront payment and potential milestones exceeding $2 billion.